2026.02.24 诺和诺德股价自2024年达到峰值以来，目前市值已缩水超过4700亿美元，抹去了2021年司美格鲁肽减重 药上市带来的全部涨幅。该公司在2024年甚至一度成为欧洲市值最高的上市制药公司。 当天，礼来公司股价受诺和诺德疲弱临床数据的提振大涨，市值重新逼近1万亿美元。礼来预计，2026 年替尔泊肽减重药需求仍将实现快速增长。该公司还预计将在今年第二季度推出口服减重药 orforglipron。届时该药物与已经获批的诺和诺德口服司美格鲁肽减重药的竞争将进一步加剧。 本文字数：947，阅读时长大约2分钟 作者 |第一财经 钱童心 当地时间2月23日，减重药司美格鲁肽厂商诺和诺德称，该公司的新一代减重药CagriSema头对头比较礼 来减重药替尔泊肽的三期临床试验结果显示，在84周内CagriSema实现减重23%。这一疗效不及礼来替 尔泊肽25.5%的减重疗效。 2026年对于诺和诺德而言是关键之年。该公司的司美格鲁肽市场份额正面临以礼来为首的多家竞争对手 的挤压。今年在中国市场，司美格鲁肽的核心分子专利也将面临到期，这意味着将有大量廉价的仿制药 可以上市。 诺和诺德曾将CagriSema定位成司 ...

Core Insights - Novo Nordisk's recent trial data for its obesity drug CagriSema has underperformed compared to Eli Lilly's Zepbound, raising concerns about Novo's competitiveness in the weight-loss drug market [1] - Following the trial results, Novo's shares dropped by 16%, while Lilly's shares increased by 5%, indicating a shift in market sentiment towards Lilly's products [1] - Analysts express skepticism about Novo's ability to regain market share, citing repeated disappointments with CagriSema and the strong positioning of Lilly's portfolio [1] Novo Nordisk's Performance - CagriSema achieved a 23% reduction in body weight over 84 weeks, compared to a 25.5% reduction for Lilly's tirzepatide [1] - The trial results align with previous data for CagriSema but are seen as inferior to Lilly's offerings, which could solidify Lilly's dominance in the obesity market [1] - Novo's management attempted to downplay the trial results, but analysts and investors remain unconvinced, questioning the drug's value proposition [1] Market Dynamics - The obesity drug market is increasingly favoring Lilly, which has a stronger product range and is expected to receive U.S. approval for its weight-loss pill in April [1] - Novo's historical lead in the obesity drug market, particularly with the launch of Wegovy in 2021, has diminished as Lilly's valuation has surged to a trillion dollars [1] - Analysts suggest that Novo may struggle to compete effectively against Lilly's Zepbound, which is already well-established in the market [1]

2026年对于诺和诺德而言是关键之年。该公司的司美格鲁肽市场份额正面临以礼来为首的多家竞争对手 的挤压。在中国市场，司美格鲁肽的核心分子专利也将面临到期。 当地时间2月23日，减重药司美格鲁肽厂商诺和诺德称，该公司的新一代减重药CagriSema头对头比较礼 来减重药替尔泊肽的三期临床试验结果显示，在84周内CagriSema实现减重23%。这一疗效不及礼来替 尔泊肽25.5%的减重疗效。 CagriSema结合了模仿胰腺激素淀粉的成分Cagrilintide和GLP-1成分司美格鲁肽，该药物每周注射一次。 诺和诺德股价自2024年达到峰值以来，目前市值已缩水超过4700亿美元，抹去了2021年司美格鲁肽减重 药上市带来的全部涨幅。该公司在2024年甚至一度成为欧洲市值最高的上市制药公司。 诺和诺德当天股价收盘暴跌超过16%，不仅创下2021年6月以来新低，也抹去了上一代减重药司美格鲁 肽上市以来的所有涨幅。 当天，礼来公司股价受诺和诺德疲弱临床数据的提振大涨，市值重新逼近1万亿美元。礼来预计，2026 年替尔泊肽减重药需求仍将实现快速增长。该公司还预计将在今年第二季度推出口服减重药 orforglipron ...

Summary of Key Points from Conference Call Industry Overview - The conference call discusses the global business development (BD) activities in the pharmaceutical sector during the Chinese New Year period from February 13 to February 23, 2026, highlighting a total of 18 BD transactions globally [1] Core Insights and Arguments - **Key Transactions**: - Qinhai Bio licensed its MAT2A inhibitor (GH31), which has received IND approval in China and the US and is currently in Phase I clinical trials, to Gilead. Qinhai will receive an upfront payment of $80 million, $1.45 billion in milestone payments, and a tiered double-digit percentage royalty based on net sales [1] - Other notable transactions include: - Novartis partnered with Unnatural Products to develop macrocyclic peptide drugs, focusing on cardiovascular applications, with Unnatural Products receiving an upfront payment of $100 million and potential milestone payments of $1.7 billion [1] - Eli Lilly acquired global rights for the IL6 monoclonal antibody clazakizumab from CSL for all indications except end-stage renal disease, with CSL receiving an upfront payment of $100 million [1] - Merck collaborated with Mayo Clinic to integrate clinical and genomic data, focusing on early research translation in inflammatory bowel disease, skin diseases, and neurology [1] - **Year-to-Date Transactions**: - From January 1 to February 23, 2026, there have been 36 BD transactions involving Chinese companies, with 13 of these transactions involving multinational corporations (MNCs) [1] Additional Important Insights - **Comparison with Previous Year**: - In comparison, there were 26 BD transactions during the same period in 2025, with only 3 involving MNCs [2] - **Future Outlook**: - The analysis indicates that MNCs have increased their focus on Chinese BD teams and asset searches since the second half of 2025, suggesting a positive outlook for more BD transactions involving Chinese assets and MNCs in 2026 [2]

Market Overview - The U.S. markets experienced a mixed day, with a focus on the U.S. 2-year yield rising by four basis points following a Supreme Court ruling that raised questions about inflation and interest rates [2][6] - Gold prices increased as investors reacted to the risk-off sentiment in the market, while tech stocks, particularly in the software sector, saw declines of approximately 1.5% [2][4] Technology Sector - The software sector is facing significant pressure, with fears that AI tools may replace traditional software suites, leading to a 30% decline in an index of stocks including Salesforce and Adobe since their record highs [4][70] - Companies like IBM have seen substantial stock declines, with IBM down over 13% amid concerns about AI disruption [70][77] Payment and Delivery Services - PayPal's stock rose nearly 5% due to takeover interest, contrasting with the broader tech sector's struggles [3] - Delivery service companies such as DoorDash and Uber are facing challenges as hypothetical scenarios suggest that AI could disrupt their business models, contributing to stock declines [5][71] Tariff and Trade Implications - The Supreme Court ruling on tariffs has created uncertainty, particularly for major importers like Home Depot and TJX, as the market grapples with the implications of potential tariff changes [6][80] - The Attorney General of Nevada indicated that states are considering actions to recover tariffs collected, which could amount to hundreds of billions of dollars [22][23] Economic Indicators - The current economic environment shows signs of growth, with global growth rates around 2.5% and 3% including emerging markets, while inflation is gradually decreasing [10][17] - The bond market is experiencing a steepening yield curve, driven by long-term inflationary concerns and an excess supply of government debt [12][14] Trucking and Transportation Sector - The trucking industry is witnessing structural changes, with a significant reduction in driver availability leading to higher rates and potential long-term impacts on capacity [57][68] - Demand for transportation services is still down year-over-year, but there are positive indicators such as increased trade volumes and a projected recovery in the second half of the year [59][63]

Among the 11 major sectors of the S&P 500, financials were down the most, while consumer staples enjoyed the largest percentage gain. The healthcare index advanced, with a boost from Eli Lilly after rival Novo Nordisk's obesity drug CagriSema underperformed Eli Lilly's drug Zepbound in a head-to-head trial. Among other movers, Domino's Pizza surged after the fast-food chain's fourth-quarter same-store sales beat Wall Street estimates. PayPal jumped following a Bloomberg report that the payments firm is att ...

｜2026年2月24日星期二｜ NO.1 Claude Code更新编程语言优化，IBM跌超13% 点评：该战略强化了市场对自动驾驶从技术验证迈向商业运营阶段的预期，为出行平台、自动驾驶技术 公司及物流板块注入了新的增长动能。 点评：此举显著降低了企业采用智能体技术的门槛，为OpenAI拓展高价值企业市场提供了关键渠道。 NO.3 礼来公司推出减肥药Zepbound新剂型 当地时间2月23日，礼来推出了其热门减肥药Zepbound的新剂型，一支笔即可提供一个月的剂量。最低 剂量级别的起步价为每月299美元。礼来第四季度财报显示，Zepbound在美国的收入达到42亿美元，较 上年同期增长122%。 点评：此举正值竞争对手诺和诺德新药临床数据不及预期之际，进一步强化了礼来在减重药市场的优 势。 NO.4 Uber成立自动驾驶汽车部门 当地时间2月23日，Uber宣布成立名为Uber Autonomous Solutions的新部门，旨在承担与运营无人驾驶出 租车、自动驾驶卡车或人行道送货机器人业务相关的所有任务，包括软件和支持服务。该部门的最终目 标是帮助自动驾驶技术公司降低每英里成本，并加快产品上市速度。Ub ...

NO.1和铂医药就新一代CTLA-4抗体达成授权协议及股权合作 2月23日，基石药业公告称，舒格利单抗的新适应证申请已获英国药品和医疗保健用品管理局批准单药 用于治疗肿瘤细胞PD-L1表达≥1%、无表皮生长因子受体敏感突变或ALK、ROS1基因组变异、在含铂 放化疗后未出现疾病进展的、不可切除的III期非小细胞肺癌成人患者。 丨2026年2月24日 星期二丨 2月23日，和铂医药公告称，公司与SOLSTICE ONCOLOGY就HBM4003订立授权协议及股权合作协 议。据此，公司同意向Solstice Oncology授予独家授权，以在大中华区以外地区开发及商业化其临床阶 段组合资产HBM4003。根据该等协议的条款，公司有资格获得价值超过1.05亿美元的前期对价。 点评：本次交易标志着和铂医药的平台技术获得国际认可，股权合作模式深度绑定双方利益，有助于降 低海外开发风险，短期利好现金流补充与估值修复，长期需关注海外临床推进节奏及里程碑兑现情况。 NO.2前沿生物与葛兰素史克签署授权许可协议 2月23日，前沿生物公告称，公司与葛兰素史克（GSK）达成一项独家授权许可协议。据此，葛兰素史 克将获得两款小核酸（ ...

兄弟姐妹们啊，临近A股开盘，今晚美股直接上演大跳水，道指大跌约700点，都不知道是不是故意的！ 一起看看发生了什么事情。 美股大跳水 2月23日晚间，美股三大指数下跌，道指直线大跳水跌超700点，纳斯达克指数、标普500指数均跌约1%。 | 纳斯达克综合指数(NASDAQ:.IXIC) | | | | 加自选 | | | --- | --- | --- | --- | --- | --- | | 22640.99 -245.08 -1.07% | | | 交易中 02-23 10:55:05 美东时间 | 35.45 万球友关注 | | | 最高: 22893.22 52周最高: 24019.99 | 今开: 22840.97 | | 量比: 1.82 | | | | 最低:22640.66 | 昨收:22886.07 | 52周最低: 14784.03 | 振幅: 1.10% | | | | 成交量: 31.23亿股 | | | | | | | 分时 五日 日K 周K 月K 季K 年K 120分 60分 30分 15分 5分 1分 | | | | 区间统计 全屏显示 | | | 最新:22640.99-24 ...

2月24日，明晟公司（MSCI）编制的北欧国家指数单日下挫2.4%，收报383.03点，创下2025年7月29日 以来最大单日跌幅。在该指数涵盖的十个板块中，医疗保健板块领跌，权重股诺和诺德当日暴跌 16.5%，成为北欧个股中表现最差的标的。 诺和诺德股价的剧烈波动，源于其新一代减肥药CagriSema的临床数据未达预期。2月23日，这家丹麦制 药巨头公布了REDEFINE 4试验结果——CagriSema在84周内实现了23%的减重效果，但研究未能达到预 设的主要目标，且在头对头比较中不及竞争对手礼来的Zepbound。诺和诺德方面也承认，CagriSema在 该试验中的表现未能证明其不劣于礼来的替尔泊肽。 摩根士丹利在研报中将此次数据结果定性为"最坏情形"。杰富瑞迈克尔·洛伊希滕在研报中指出："真正 令人头疼的是，诺和诺德的终值估值高度依赖amycretin，而该药和CagriSema一样，都是GLP-1/胰淀素 双靶点药物（只不过是单分子）。因此REDEFINE-4试验失利，叠加竞争带来的商业化不确定性，很难 让长线投资者安心。"摩根大通克里斯·肖特在研报中表示："这一结果证实，Zepbound目前是明 ...